Episode 29: Asia’s 2025 Q2 Report: Global Trends in Biopharma Transactions

During the Asia-focused Episode 29 of Biotalk, Geoff shares insights into key trends and developments shaping the biotech landscapes in Japan, China, Korea, Australia, and the broader Asia-Pacific region, as featured in our 2025 Q2 Report: Global Trends in Biopharma Transactions Report.

Japan’s biotech stocks outperformed broader indices, boosted by regulatory reforms and Shionogi’s $1.1B acquisition of Japan Tobacco’s pharma units. Licensing slowed, while early-stage financings focused on preclinical firms.

China’s biotech market surged with four HKEX IPOs raising $1.5B. Venture funding fell as risk aversion grew, but strategic licensing stayed strong at $24.4B, shifting toward later-stage oncology and obesity deals.

Korea’s biotech index dipped but showed 12-month gains, driven by ABL Bio’s $2.8B licensing deal with GSK and key Series B financings.

Listen now to gain insights into the evolving global biopharma landscape, explore our report, and we welcome the opportunity to discuss its contents with you.